Rep. Gabe Vasquez

Maddy summaryHR 5791, the BLOOD Centers Act, creates a 30-day expedited approval process for blood centers seeking to add apheresis collection devices to existing biologics licenses. It directly affects blood centers operating under FDA biologics licenses that already manage multiple locations or hold accredited status. The bill requires the FDA to approve such applications within 30 days unless safety concerns exist at the specific location or the center has systemic safety failures elsewhere. This streamlines the process for expanding blood collection capabilities without compromising safety standards.

Maddy summaryHR 647, the Ensuring Veterans’ Final Resting Place Act of 2025, amends a provision in U.S. Code (38 U.S.C. § 2306(h)) to change how burial benefits are provided for veterans. It removes the requirement that a veteran’s family must provide an urn or plaque for the Department of Veterans Affairs (VA) to offer additional burial benefits; the VA will now automatically provide these benefits regardless of whether the family supplies such items. This change directly affects veterans’ families arranging burial services, making it easier to access burial benefits without needing to procure specific items first. The amendment applies to veterans who die on or after January 5, 2021, updating existing eligibility rules.

Maddy summaryThis bill adds Medicare coverage for multi-cancer early detection screening tests (blood or biological tests analyzing cell-free DNA) starting January 1, 2028. It directly affects Medicare beneficiaries aged 68 and older (starting in 2028, with the age limit increasing by 1 year annually), requiring tests to be FDA-cleared and deemed reasonable/necessary by the Secretary for early cancer detection across multiple organ sites. Payment will initially match current stool DNA test rates before 2031, then shift to a lower rate or new payment system after 2031, with limits preventing more than one test per year. The bill explicitly states it does not alter coverage for existing cancer screenings like breast, colorectal, or prostate cancer tests.

Maddy summaryHRES 772 is a symbolic House resolution expressing support for National Public Lands Day (observed September 27, 2025). It encourages U.S. citizens to visit public lands on this fee-free day, recognizing their cultural, spiritual, and economic value. The resolution cites existing statistics on public lands' economic contributions (e.g., $252 billion in economic output from Bureau of Land Management lands in 2024) but does not create new policies or alter fees. As a procedural resolution, it has no binding effect and serves only to promote awareness of existing public land access.

Maddy summaryThe Patients Deserve Price Tags Act (HR 5582) requires hospitals, clinical diagnostic laboratories, imaging services providers, and ambulatory surgical centers to publicly disclose detailed pricing information for healthcare services. This includes standard charges, discounted cash prices, and payer-specific negotiated rates for each item or service, presented in machine-readable formats and consumer-friendly displays. Implementation deadlines are set for 2026 for hospitals and 2027 for other providers, with civil monetary penalties for non-compliance ranging from $300 per day for smaller facilities to up to $10,000,000 annually for health plans. The legislation aims to increase price transparency so consumers can better understand and compare healthcare costs before receiving services.

Maddy summaryHR 5586, the TRICARE Transition Transparency Act of 2025, requires the Department of Defense to provide advance written notices to military health care beneficiaries about upcoming changes to their TRICARE coverage. Beneficiaries affected by required plan changes (such as due to age) will receive three electronic notices: one year, 180 days, and 30 days before the transition. The bill also mandates an annual outreach campaign via website, social media, and family groups, plus yearly reports to Congress on implementation progress. This law aims to improve beneficiary awareness of coverage transitions without altering TRICARE plan options or costs.

Maddy summaryThe Mental Health Services for Students Act of 2025 would establish a federal grant program to fund school-based mental health services for students in grades K-12, particularly those experiencing trauma, grief, suicide risk, or violence. It directly affects schools (including Bureau of Indian Education schools), students, and community mental health providers through partnerships that must include school districts and local mental health entities. Key provisions require services to be culturally appropriate, trauma-informed, and integrated with positive behavioral supports, with grants capped at $2 million per award for 5 years (renewable) and funded at $300 million annually for 2027-2028. Recipients must report annually on program outcomes, ensure equitable access across urban and rural areas, and comply with privacy laws like HIPAA and FERPA.

Maddy summaryHR 5526, the Biosimilar Red Tape Elimination Act, streamlines the U.S. Food and Drug Administration’s (FDA) process for approving biosimilar drugs that can be used interchangeably with brand-name biologic medications. It establishes a 60-day transition period after enactment to clarify when biosimilars are deemed "interchangeable" with reference drugs, preserving existing exclusivity periods for products licensed before the law’s passage. This affects pharmaceutical manufacturers developing biosimilars, the FDA (which must update its guidance within 18 months), and healthcare systems seeking lower-cost treatment options. The bill removes redundant language from existing laws and ensures the FDA’s approval standards for biosimilars remain unchanged, focusing on regulatory clarity rather than altering drug safety or efficacy requirements.

Maddy summaryThis bill requires health plans and insurers to create a clear, timely process for patients or doctors to request exceptions when step therapy protocols (which force patients to try cheaper drugs first) might harm them. It mandates approval for exceptions in six specific cases, such as when prior treatments failed, delaying care risks severe harm, or the required drug causes adverse reactions. Plans must respond within 72 hours (24 hours for emergencies) and cover the requested drug for at least one year if approved. Additionally, health plans must report annual data on exception requests, approvals, denials, and reasons to the government for transparency.

Maddy summaryThe HEADACHE Act establishes a National Headache Disorders Initiative (NHDI) under the Department of Health and Human Services to address conditions like migraines, cluster headaches, and other headache disorders affecting vulnerable groups including children, pregnant women, and older adults. It creates an Advisory Council with patient advocates, healthcare providers, and federal agency representatives to guide research, improve diagnosis protocols, and reduce disparities in care. The bill requires federal agencies to share headache-related data and mandates an annual congressional report evaluating progress, disparities across demographics, and recommendations for better access to treatment and stigma reduction, with the initiative set to expire after five years.